UPLOAD Filing
BIO-PATH HOLDINGS, INC.
Date: April 1, 2026 · CIK: 0001133818 · Accession: 0000000000-26-003337
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 024-12728
Letter
April 1, 2026 Vikram Grover Chief Executive Officer BioPath Holdings, Inc. 625 Stanwix St. #2407 Pittsburgh, PA 15222 Re:BioPath Holdings, Inc. Offering Statement on Form 1-A Filed March 25, 2026 File No. 024-12728 Dear Vikram Grover: This is to advise you that we do not intend to review your offering statement. We will consider qualifying your offering statement at your request. In connection with your request, please confirm in writing that at least one state has advised you that it is prepared to qualify or register your offering. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Sean Doney
Show Raw Text
April 1, 2026
Vikram Grover
Chief Executive Officer
BioPath Holdings, Inc.
625 Stanwix St. #2407
Pittsburgh, PA 15222
Re:BioPath Holdings, Inc.
Offering Statement on Form 1-A
Filed March 25, 2026
File No. 024-12728
Dear Vikram Grover:
This is to advise you that we do not intend to review your offering statement.
We will consider qualifying your offering statement at your request. In connection with
your request, please confirm in writing that at least one state has advised you that it is prepared
to qualify or register your offering. If a participant in your offering is required to clear its
compensation arrangements with FINRA, please have FINRA advise us that it has no objections
to the compensation arrangements prior to qualification.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Sean Doney